Hepatology

Article	Citations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	2148
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s	1848
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	1660
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	1134
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	441
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	317
Late-Breaking Abstracts	262
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	236
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	234
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	226
Cover Image	226
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	226
Alan Hofmann (1931‐2021): A career well spent understanding bile acids	205
Retracted: M2 Macrophage–Derived Exosomes Facilitate HCC Metastasis by Transferring αMβ2 Integrin to Tumor Cells	197
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	190
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	186
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	183
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	182
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	181
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	179
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis	167
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation	159
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	150
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	150
Reply	145

Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	144
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	141
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	141
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	133
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients	126
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	123
Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	120
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	119
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	118
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis	116
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	116
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	115
Efficacy and safety of infliximab in patients with autoimmune hepatitis	115
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	114
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	112
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	104
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	104
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	104
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	100
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	100
Access to technology to support telehealth in areas without specialty care for liver disease	99
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	98
Regulatory role and translational potential of CCL11 in liver fibrosis	98
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	96
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	96
	95
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	93
Genes that fit just right: Unzipping the genome of fatty liver disease	92
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	92
Therapeutic manipulation of the microbiome in liver disease	91
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?	91
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	91
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	91
Reply	91
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	90
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	90
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	89
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans	87
	87
Reply: The CRAPT-M score: Robust enough for clinical practice?	87
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement	87
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism	85
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	84
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer	83
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	83
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	82
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	82
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	81
Letter to the Editor: Overlooking the important factor: Hypoxia	81
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	81

Letter to the editor	80
The digital determinants of liver disease	79
Instructions to Authors	78
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	78
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	75
Dedifferentiation‐associated inflammatory factors of long‐term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment	73
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination	73
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty	72
Letter to the Editor: Screening and risk stratification disparities in Hispanic MASLD	72
Letter to the Editor: Insights into immune-mediated adverse events and survival outcomes—Lessons from HIMALAYA	72
Reply: Diabetes and fibrosis—Parallel risks or overlap?	71
Healthy peribiliary glands are necessary for successful liver transplantation	71
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation	70
Much more needed in natural history of Alagille syndrome	70
The international quest for the imaging diagnosis of liver cancer	70
Immunobiology of primary sclerosing cholangitis	70
Erratum	70
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	69
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers	69
In vivo imaging of calcium dynamics in zebrafish hepatocytes	68
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome	67
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis	66
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness	66
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	66
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH	65
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?	64
Outcomes of pregnancy in autoimmune hepatitis: A population‐based study	64
A strategy of vascular‐targeted therapy for liver fibrosis	64
Metabolic dysfunction-associated steatotic liver disease and the heart	64
Fontan‐associated liver disease	64
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis	63
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	63
Magnetic resonance elastography for prediction of long‐term progression and outcome in chronic liver disease: A retrospective study	63
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature	63
NAFLD‐related hepatocellular carcinoma: The growing challenge	62
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response	62
The clot and the complicated consult	61
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease	61
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease	60
Letter to the Editor: Peripheral Foxp3-high Tregs as a dual biomarker for HCC prognosis and immunotherapy response	60
Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease	60
Serum amyloid A1–induced intrahepatic regulatory T-cell dysfunction drives autoimmune hepatitis progression	60
E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants	59
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis	59
Oral Abstracts	59
Early detection of primary liver cancer using plasma cell‐free DNA fragmentomics: Do all the pieces come together?	59
Reply	58
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block	58
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia	57
SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling	57
Reply	57
Manuscript best practices: Takeaways from a community conversation	57
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	56
Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort	56
Reply	56
Reply	56
The “shell game” after objective response in patients with advanced HCC treated with immunotherapy	55
Letter to the editor: RECAM for the diagnosis of DILI—Is it time to incorporate additional pharmacological criteria?	54
Hepatology Highlights	54
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	54
Letter to the editor: Considerations on the use of the liver transplant comorbidity index (LTCI)	53
Reply	53
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy	53
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis	52
Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS	52
Integrative Hepatology: Enhancing overall health to manage liver disease	52
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation	52
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease	52
Letter to Editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function	52
Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Sh	51
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States	50
Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	50
Glutamine synthetase loss in β-catenin–mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming	50
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC	50
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase	50
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles	50
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study	50
Pathway to global elimination of hepatitis B: HBV cure is just the first step	50
Future directions in acute liver failure	50
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study	49

Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study	49
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases	49
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation	48
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution	48
Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	48
Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study	48
Letter to the Editor: Exchangeable copper in the Danish cohort of patients with Wilson disease	48
Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol	48
A bright future: Sustainable treatment of gastric varices	48
PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features	47
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent	47
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies	47
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”	47
Masthead	46
Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions	46
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?	46
Prognostic significance of mild ascites in patients with cirrhosis	46
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices	46
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency	46
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD	45
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors	45
Intrahepatic cholangiocarcinoma PANoptosidy	45
Predicting liver outcomes with biomarker monitoring in MASLD	45
Letter to the Editor: The profile of HBsAg levels after nucleos(t)ide analogues treatment is crucial for achieving functional cure	44
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations	44
Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure	44
Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease	44
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study	44
Hepatocyte‐derived MASP1‐enriched small extracellular vesicles activate HSCs to promote liver fibrosis	44
Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis	44
Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?	43
Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma	43
Masthead	43
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC	43
Letter to the Editor: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma	43
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab	43
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations	43
Table of contents	43
Letter to the editor: High rate of clinical and immunological response in patients with HCV‐associated cryoglobulinemia	42
Reply	42
Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?	41
Corticosteroids for high‐grade immune checkpoint inhibitor–mediated hepatitis: Is less more?	41
Reply	41
Cover Image	41
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys	41
Letter to the editor: Relevance of population‐based cutoffs to define frailty in clinical studies	41
Erratum for Ren, H et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of hepatocyte nuclear factor 4α	41
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality	40
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease	40
Letter to the editor: HuR in liver homeostasis	40
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west	40
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!	40
Letter to the Editor: More questions than answers—Response to the POP-NEXT project	40
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury	39
Letter to the Editor: Key advance in noninvasive fibrosis assessment: Evidence from China	39
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets	39
The Liver Meeting: 2025 Abstracts	39
Telehealth interventions in patients with chronic liver diseases: A systematic review	39
Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy	39
Imaging for better responses to immunotherapy in hepatocellular carcinoma	39
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease	39
Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV‐specific T‐cell response and homing	38
Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs	38
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon	38
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study	38
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination‐deficient hepatocellular carcinoma	38
Letter to the Editor: There may be a misunderstanding about the function of circular RNA as miRNA sponges	38
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis	37
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial	37
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC	37
Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study	37
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase	37
Tripartite motif‐containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen‐activated protein kinase kinase kinase 7	36
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI	36
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis	36
The evolving role of liver sinusoidal endothelial cells in liver health and disease	36
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population	36
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis	36
A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver D	36
A global action agenda for turning the tide on fatty liver disease	36
Letter to the editor: Loss of Sam50 in hepatocytes induces cardiolipin‐dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury	35
Dynamic duo: Spleen stiffness and bilirubin revolutionize PSVD screening	35
Letter to the Editor: Assessing HCC risk in HBV indeterminate phase	35
BileMet: A new frontier in distinguishing malignant from benign biliary conditions	35
Category Index	35
Letter to the Editor: Use of HBV RNA and to predict change in serological status and disease activity in CHB	35
Letter to the Editor: Re-evaluating the clinical relevance of the RIPPLY1-TBX19 axis in CTNNB1-mutant hepatocellular carcinoma	35
Category Index	35
Reply: Revisiting FOXP3 expression and its prognostic implications in hepatocellular carcinoma	35
RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1-mutated hepatocellular carcinoma	35
Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice	34
Technical systematic review supporting 2025 AASLD practice guidelines on management of chronic hepatitis B	34
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study	34
Gut-to-bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders	34
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study	34